Disease · HP_0100578
Lipoatrophy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Lipoatrophy. Diseases, record HP_0100578. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0100578
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Lipoatrophy
- Open Targets ID
- HP_0100578
- Other names
- Atrophy of fat, Loss of fat tissue in localised area, Loss of fat tissue in localized area
- Highest stage of its drugs
- Phase 3, for 1 of its 11 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PIOGLITAZONE | CHEMBL595 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| URIDINE | CHEMBL100259 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ROSIGLITAZONE | CHEMBL121 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ABACAVIR | CHEMBL1380 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ATAZANAVIR | CHEMBL1163 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LOPINAVIR | CHEMBL729 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NEVIRAPINE | CHEMBL57 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RITONAVIR | CHEMBL163 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| STAVUDINE | CHEMBL991 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TENOFOVIR | CHEMBL3989702 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | 2 | Peroxisome proliferator-activated receptor gamma agonist | Phase 3 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| CYP3A4 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Unknown | https://conductscience.org/library/genes/1576 | Drugs and targets |
| CYP3A43 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Unknown | https://conductscience.org/library/genes/64816 | Drugs and targets |
| CYP3A5 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Unknown | https://conductscience.org/library/genes/1577 | Drugs and targets |
| CYP3A7 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Unknown | https://conductscience.org/library/genes/1551 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00307164 | Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy | Phase 2/3 | 167 | 2011-10-04 | HIV Infections, Lipoatrophy | URIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00367744 | Rosiglitazone Effect on Mitochondria and Lipoatrophy | Phase 2 | 71 | 2017-02-06 | HIV Infections | ROSIGLITAZONE | Its record names the disease | ClinicalTrials.gov |
| NCT00028314 | Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients | Not applicable | 150 | HIV Infections, Lipodystrophy, Wasting Disease | ABACAVIR, ATAZANAVIR, LOPINAVIR, NEVIRAPINE, RITONAVIR, STAVUDINE, ZIDOVUDINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00148850 | Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients | Phase 3 | 130 | HIV-Associated Lipodystrophy Syndrome, HIV Infections | PIOGLITAZONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00225082 | SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function | 12 | HIV Infection | TENOFOVIR | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NucleomaxX vs Placebo: Number of Subjects Discontinuing Study Medication | 34 of 83 | 34 of 82 | 165 | NCT00307164 | Trial comparisons |
| NucleomaxX vs Placebo: serious adverse events | 4 of 83 | 2 of 82 | 165 | NCT00307164 | Trial comparisons |
| Rosiglitazone vs Placebo: serious adverse events | 15 of 34 | 13 of 37 | 71 | NCT00367744 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0100578
GET https://conductscience.org/api/diseases/v1/HP_0100578/drugs